Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis

Noriko Tatebe, Kenei Sada, Yosuke Asano, Sonia Zeggar, Sumie Hiramatsu, Yoshia Miyawaki, Keiji Ohashi, Michiko Morishita, Takayuki Katsuyama, Eri Katsuyama, Haruki Watanabe, Mariko Narazaki, Katsue Watanabe, Tomoko Kawabata, Jun Wada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The objective of this study is to elucidate predictors of relapse in patients with polymyositis and dermatomyositis (PM/DM). Methods: Fifty PM/DM patients who achieved disease stabilization at Okayama University Hospital in 2004–2014 were enrolled retrospectively. Candidate predictors such as demographic factors, clinical symptoms, laboratory data, and treatment status were compared. Results: The mean age of enrolled patients was 58 years; 34 were female. The patient groupings were as follows: 21 with PM, 27 with DM, and two with clinically amyopathic DM. During a mean observation period of 685 d, 5 patients (10%) died and 20 (40%) relapsed. The relapsed patients displayed baseline muscle weakness less frequently (85% versus 100%, p = .03) and anti-SS-A/Ro antibody more frequently (65% versus 27%, p = .007). Anti-SS-A/Ro-positive patients exhibited a higher relapse rate than anti-SS-A/Ro-negative patients (log-rank test, p = .03). Anti-SS-A/Ro-positive patients also exhibited higher anti-Jo-1 antibody positivity and lower levels of serum complement. After adjusting anti-Jo-1 antibody positivity, age, sex, CK <500 IU/L, and lung involvement, anti-SS-A/Ro positivity was still an independent risk factor for higher relapse-rate (odds ratio, 5.5; 95% confidence interval, 1.4–25.1). Conclusions: Anti-SS-A/Ro antibody positivity may be a useful biomarker for prediction of relapse.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - May 2 2017

Fingerprint

Dermatomyositis
Recurrence
SS-A antibodies
Muscle Weakness
Biomarkers
Odds Ratio
Observation
Demography
Confidence Intervals
Lung

Keywords

  • Anti-SS-A/Ro antibodies
  • dermatomyositis
  • polymyositis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. / Tatebe, Noriko; Sada, Kenei; Asano, Yosuke; Zeggar, Sonia; Hiramatsu, Sumie; Miyawaki, Yoshia; Ohashi, Keiji; Morishita, Michiko; Katsuyama, Takayuki; Katsuyama, Eri; Watanabe, Haruki; Narazaki, Mariko; Watanabe, Katsue; Kawabata, Tomoko; Wada, Jun.

In: Modern Rheumatology, 02.05.2017, p. 1-6.

Research output: Contribution to journalArticle

Tatebe, N, Sada, K, Asano, Y, Zeggar, S, Hiramatsu, S, Miyawaki, Y, Ohashi, K, Morishita, M, Katsuyama, T, Katsuyama, E, Watanabe, H, Narazaki, M, Watanabe, K, Kawabata, T & Wada, J 2017, 'Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis', Modern Rheumatology, pp. 1-6. https://doi.org/10.1080/14397595.2017.1317377
Tatebe, Noriko ; Sada, Kenei ; Asano, Yosuke ; Zeggar, Sonia ; Hiramatsu, Sumie ; Miyawaki, Yoshia ; Ohashi, Keiji ; Morishita, Michiko ; Katsuyama, Takayuki ; Katsuyama, Eri ; Watanabe, Haruki ; Narazaki, Mariko ; Watanabe, Katsue ; Kawabata, Tomoko ; Wada, Jun. / Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. In: Modern Rheumatology. 2017 ; pp. 1-6.
@article{da39d55442b54d22a6f61a0a4640d92c,
title = "Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis",
abstract = "Objective: The objective of this study is to elucidate predictors of relapse in patients with polymyositis and dermatomyositis (PM/DM). Methods: Fifty PM/DM patients who achieved disease stabilization at Okayama University Hospital in 2004–2014 were enrolled retrospectively. Candidate predictors such as demographic factors, clinical symptoms, laboratory data, and treatment status were compared. Results: The mean age of enrolled patients was 58 years; 34 were female. The patient groupings were as follows: 21 with PM, 27 with DM, and two with clinically amyopathic DM. During a mean observation period of 685 d, 5 patients (10{\%}) died and 20 (40{\%}) relapsed. The relapsed patients displayed baseline muscle weakness less frequently (85{\%} versus 100{\%}, p = .03) and anti-SS-A/Ro antibody more frequently (65{\%} versus 27{\%}, p = .007). Anti-SS-A/Ro-positive patients exhibited a higher relapse rate than anti-SS-A/Ro-negative patients (log-rank test, p = .03). Anti-SS-A/Ro-positive patients also exhibited higher anti-Jo-1 antibody positivity and lower levels of serum complement. After adjusting anti-Jo-1 antibody positivity, age, sex, CK <500 IU/L, and lung involvement, anti-SS-A/Ro positivity was still an independent risk factor for higher relapse-rate (odds ratio, 5.5; 95{\%} confidence interval, 1.4–25.1). Conclusions: Anti-SS-A/Ro antibody positivity may be a useful biomarker for prediction of relapse.",
keywords = "Anti-SS-A/Ro antibodies, dermatomyositis, polymyositis",
author = "Noriko Tatebe and Kenei Sada and Yosuke Asano and Sonia Zeggar and Sumie Hiramatsu and Yoshia Miyawaki and Keiji Ohashi and Michiko Morishita and Takayuki Katsuyama and Eri Katsuyama and Haruki Watanabe and Mariko Narazaki and Katsue Watanabe and Tomoko Kawabata and Jun Wada",
year = "2017",
month = "5",
day = "2",
doi = "10.1080/14397595.2017.1317377",
language = "English",
pages = "1--6",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis

AU - Tatebe, Noriko

AU - Sada, Kenei

AU - Asano, Yosuke

AU - Zeggar, Sonia

AU - Hiramatsu, Sumie

AU - Miyawaki, Yoshia

AU - Ohashi, Keiji

AU - Morishita, Michiko

AU - Katsuyama, Takayuki

AU - Katsuyama, Eri

AU - Watanabe, Haruki

AU - Narazaki, Mariko

AU - Watanabe, Katsue

AU - Kawabata, Tomoko

AU - Wada, Jun

PY - 2017/5/2

Y1 - 2017/5/2

N2 - Objective: The objective of this study is to elucidate predictors of relapse in patients with polymyositis and dermatomyositis (PM/DM). Methods: Fifty PM/DM patients who achieved disease stabilization at Okayama University Hospital in 2004–2014 were enrolled retrospectively. Candidate predictors such as demographic factors, clinical symptoms, laboratory data, and treatment status were compared. Results: The mean age of enrolled patients was 58 years; 34 were female. The patient groupings were as follows: 21 with PM, 27 with DM, and two with clinically amyopathic DM. During a mean observation period of 685 d, 5 patients (10%) died and 20 (40%) relapsed. The relapsed patients displayed baseline muscle weakness less frequently (85% versus 100%, p = .03) and anti-SS-A/Ro antibody more frequently (65% versus 27%, p = .007). Anti-SS-A/Ro-positive patients exhibited a higher relapse rate than anti-SS-A/Ro-negative patients (log-rank test, p = .03). Anti-SS-A/Ro-positive patients also exhibited higher anti-Jo-1 antibody positivity and lower levels of serum complement. After adjusting anti-Jo-1 antibody positivity, age, sex, CK <500 IU/L, and lung involvement, anti-SS-A/Ro positivity was still an independent risk factor for higher relapse-rate (odds ratio, 5.5; 95% confidence interval, 1.4–25.1). Conclusions: Anti-SS-A/Ro antibody positivity may be a useful biomarker for prediction of relapse.

AB - Objective: The objective of this study is to elucidate predictors of relapse in patients with polymyositis and dermatomyositis (PM/DM). Methods: Fifty PM/DM patients who achieved disease stabilization at Okayama University Hospital in 2004–2014 were enrolled retrospectively. Candidate predictors such as demographic factors, clinical symptoms, laboratory data, and treatment status were compared. Results: The mean age of enrolled patients was 58 years; 34 were female. The patient groupings were as follows: 21 with PM, 27 with DM, and two with clinically amyopathic DM. During a mean observation period of 685 d, 5 patients (10%) died and 20 (40%) relapsed. The relapsed patients displayed baseline muscle weakness less frequently (85% versus 100%, p = .03) and anti-SS-A/Ro antibody more frequently (65% versus 27%, p = .007). Anti-SS-A/Ro-positive patients exhibited a higher relapse rate than anti-SS-A/Ro-negative patients (log-rank test, p = .03). Anti-SS-A/Ro-positive patients also exhibited higher anti-Jo-1 antibody positivity and lower levels of serum complement. After adjusting anti-Jo-1 antibody positivity, age, sex, CK <500 IU/L, and lung involvement, anti-SS-A/Ro positivity was still an independent risk factor for higher relapse-rate (odds ratio, 5.5; 95% confidence interval, 1.4–25.1). Conclusions: Anti-SS-A/Ro antibody positivity may be a useful biomarker for prediction of relapse.

KW - Anti-SS-A/Ro antibodies

KW - dermatomyositis

KW - polymyositis

UR - http://www.scopus.com/inward/record.url?scp=85018452708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018452708&partnerID=8YFLogxK

U2 - 10.1080/14397595.2017.1317377

DO - 10.1080/14397595.2017.1317377

M3 - Article

C2 - 28463039

AN - SCOPUS:85018452708

SP - 1

EP - 6

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -